All In MedTech

FDA Clearance Tracker · P150038-S003

ExAblate

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jun 26, 2017 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Jun 26, 2017

Approved

Time to decision

90 days

Received Mar 28, 2017. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Normal 180 Day Track

Device class

Class III

The decision

FDA number
P150038-S003
Device name
ExAblate
Applicant
Insightec
Applicant location
Tirat Carmel
Received
Mar 28, 2017
Decided
Jun 26, 2017
Decision
Approved
Supplement type
Normal 180 Day Track
Reason for supplement
Change Design/Components/Specifications/Material
Original approval
P150038

Device type

Device class
Class III

Every decision under product code POH

FDA's approval statement

As written in FDA's record.

Approval for a software maintenance upgrade from Software Version 6.6 to Version 7.0 for the unilateral Thalamotomy treatment of idiopathic Essential Tremor (ET) patients with medication –refractory tremor.

Source documents

Other decisions for Insightec

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

5 more FDA decisions with a free account

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.